InvestSMART

Immuron Limited (ASX: IMC) - Announcements

Current share price for IMC : $0.043 0.003 (6.52%)+

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$14 Q3 FY23 Business Update Webinar 11 Apr 2023 10:18AM $0.078 $0.043 fallen by 44.87%
$14 Immuron Q3 Sales reach 150% of 1H Sales 6 Apr 2023 8:25AM $0.070 $0.043 fallen by 38.57%
$14 Notification of cessation of securities - IMC 16 Mar 2023 5:03PM $0.079 $0.043 fallen by 45.57%
$14 Appendix 4D and Half Year Report 28 Feb 2023 7:03PM $0.075 $0.043 fallen by 42.67%
$14 Business Update Presentation 28 Feb 2023 9:45AM $0.072 $0.043 fallen by 40.28%
$14 Immuron CEO Steven Lydeamore to host investor webinar 15 Feb 2023 8:04AM $0.076 $0.043 fallen by 43.42%
$14 Immuron and US NMRC respond to CampETEC FDA Clinical Hold 25 Jan 2023 9:30AM $0.081 $0.043 fallen by 46.91%
$14 US DOD Travelan Clinical Recruitment Milestone 18 Jan 2023 2:07PM $0.079 $0.043 fallen by 45.57%
$14 Immuron Receives European Patent on Drug Composition 17 Jan 2023 9:44AM $0.076 $0.043 fallen by 43.42%
$14 Change in substantial holding 30 Dec 2022 8:23AM $0.085 $0.043 fallen by 49.41%
$14 Immuron Receives FDA Approval for Travelan IND Application 23 Dec 2022 9:44AM $0.072 $0.043 fallen by 40.28%
$14 Immuron Submits IND Application To FDA for Travelan 5 Dec 2022 8:30AM $0.080 $0.043 fallen by 46.25%
$14 Amended Constitution 1 Dec 2022 2:17PM $0.082 $0.043 fallen by 47.56%
$14 Results of Annual General Meeting 21 Nov 2022 7:03PM $0.077 $0.043 fallen by 44.16%
$14 AGM Presentation 21 Nov 2022 9:10AM $0.078 $0.043 fallen by 44.87%
$14 Immuron completes strategic investment in Ateria Health 16 Nov 2022 9:46AM $0.077 $0.043 fallen by 44.16%
$14 Immuron CEO Steven Lydeamore to present at AusBioInvest 26 Oct 2022 9:53AM $0.081 $0.043 fallen by 46.91%
$14 Notice of Annual General Meeting/Proxy Form 21 Oct 2022 9:48AM $0.085 $0.043 fallen by 49.41%
$14 IMC investment in leading gut health biotech Ateria Health 13 Oct 2022 11:53AM $0.080 $0.043 fallen by 46.25%
$14 Immuron Executes Travelan Clinical Trial Agreement Pharmaron 4 Oct 2022 12:01PM $0.080 $0.043 fallen by 46.25%
$14 Appendix 4G 9 Sep 2022 4:58PM $0.088 $0.043 fallen by 51.14%
$14 Corporate Governance Statement 9 Sep 2022 4:56PM $0.088 $0.043 fallen by 51.14%
$14 Annual Report to shareholders 9 Sep 2022 4:55PM $0.088 $0.043 fallen by 51.14%
$14 FY22 Results and Business Update Presentation 31 Aug 2022 9:31AM $0.090 $0.043 fallen by 52.22%
$14 Appendix 4E and Preliminary Final Report 31 Aug 2022 9:28AM $0.090 $0.043 fallen by 52.22%

226 - 250 of 782 results

Page 10 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.